Notch Signaling Modulation Therapy for Neurodegeneration
Overview
This therapeutic concept targets dysregulated [Notch signaling](/mechanisms/notch-signaling-pathway) across Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The Notch pathway is a highly conserved cell-cell communication system with dual roles: it drives neurogenesis and synaptic plasticity when properly regulated, but contributes to pathology when disrupted. Three complementary strategies offer therapeutic benefit: ADAM10 activation to restore non-amyloidogenic APP processing and Notch cleavage, JAG1 blockade to interrupt pathological astrocyte-neuron inflammatory crosstalk, and gamma-secretase modulation to shift amyloid-beta production without impairing Notch function.
Rationale
Pathological Dysregulation
The Notch pathway intersects with multiple neurodegenerative processes:
Alzheimer's Disease: Amyloid-beta oligomers directly inhibit Notch receptor processing, reducing ADAM10-mediated cleavage and impairing NICD nuclear translocation. This contributes to synaptic plasticity deficits and accelerated cognitive decline. Reduced ADAM10 activity in AD brain promotes amyloidogenic Aβ42 production, creating a vicious cycle between Notch dysfunction and amyloid pathology.
Parkinson's Disease: Alpha-synuclein aggregates impair Notch-dependent transcription in dopaminergic neurons. Notch activity naturally declines with aging, and PD pathology accelerates this decline. JAG1-expressing astrocytes promote microglial activation through Notch-NF-κB crosstalk, propagating neuroinflammation. Meanwhile, restoring Notch signaling promotes dopaminergic neuron survival in models.
Amyotrophic Lateral Sclerosis: DLL3 is aberrantly expressed in ALS motor neurons, contributing to motor neuron vulnerability. TDP-43 proteinopathy (present in 95% of ALS cases) disrupts Notch transcriptional regulation by binding to Notch gene promoters. Notch hyperactivity contributes to the ALS phenotype, while loss of TDP-43 function further dysregulates Notch target genes.Why Notch is an Attractive Target
- Dual beneficiary: ADAM10 activation simultaneously reduces Aβ production AND promotes neuroprotective Notch signaling — the "best of both worlds" that gamma-secretase inhibitors failed to achieve due to Notch-related side effects
- Druggable pathway: Multiple intervention points (ligands, receptors, secretases, cofactors) enable tailored approaches
- Cross-disease relevance: Notch dysregulation is documented in AD, PD, ALS, and CADASIL, enabling multi-disease therapeutic strategies
- Genetic intersection: PSEN1/2 mutations (familial AD) alter both Aβ production and Notch cleavage, directly implicating Notch in disease pathogenesis
- Regenerative potential: Notch signaling enhancers could restore adult neurogenesis, addressing the fundamental loss of neuronal replacement capacity in neurodegeneration
Three-Pronged Therapeutic Strategy
Arm 1: ADAM10 Activators
Primary Target: ADAM10 (a-disintegrin-and-metalloproteinase-domain-10), the alpha-secretase that performs non-amyloidogenic APP processing and Notch receptor cleavage[@yang2021]
Mechanism:
- ADAM10 cleaves APP at the alpha-secretase site, preventing Aβ formation from the amyloidogenic pathway
- ADAM10 also cleaves Notch receptors at the S2 site, enabling subsequent gamma-secretase cleavage and NICD release
- ADAM10 expression decreases in AD brain, shifting the balance toward amyloidogenic processing
- Activating ADAM10 addresses both pathologies simultaneously
Therapeutic Approach:
- Small-molecule ADAM10 activators that enhance catalytic activity without causing off-target effects
- Allosteric modulators that increase ADAM10 substrate affinity for APP
- Protein kinase C (PKC) activators that upregulate ADAM10 expression (PKC phosphorylates ADAM9, promoting its trafficking to the membrane)
Challenges:
- Broad-spectrum metalloprotease inhibition causes off-target effects (TACE/ADAM17 is structurally similar)
- Selectivity for ADAM10 over ADAM17 requires precise targeting of the catalytic domain's S2' pocket
Arm 2: JAG1 Blockade for Neuroinflammation Control
Primary Target: JAG1 (Jagged-1), the Notch ligand expressed on astrocytes that promotes microglial activation through Notch-NF-κB crosstalk[@xia2020]
Mechanism:
- Astrocyte-expressed JAG1 engages Notch receptors on microglia, activating the Notch-NF-κB inflammatory cascade
- This pathway amplifies chronic neuroinflammation in PD, AD, and ALS
- Blocking JAG1-Notch interaction interrupts astrocyte-microglia pathological communication without globally suppressing immune function
Therapeutic Approach:
- Monoclonal antibodies against JAG1 (blocking the DSL domain that engages Notch receptors)
- JAG1-Fc fusion proteins (decoy receptors that sequester Notch receptors)
- Notch inhibitory peptides derived from the JAG1 binding interface
Challenges:
- JAG1-Notch signaling is required for normal synaptic plasticity and adult neurogenesis — systemic blockade could impair cognitive function
- Cell-type specific targeting required (microglia/astrocytes only)
Arm 3: Gamma-Secretase Modulators (GSMs)
Primary Target: Gamma-secretase complex (PSEN1/PSEN2/APh-1/PEN-2) for selective Aβ42/Aβ40 ratio modulation without Notch inhibition[@cespedes2020]
Mechanism:
- First-generation gamma-secretase inhibitors (GSIs) failed in clinical trials due to Notch-related side effects (gastrointestinal toxicity, immunosuppression)
- GSMs are not inhibitors — they shift the cleavage position of gamma-secretase, reducing toxic Aβ42 production while preserving Notch cleavage
- E-2012 and similar GSMs stabilize the interaction between gamma-secretase and APP, favoring shorter Aβ peptides (Aβ38, Aβ40) over longer aggregation-prone variants (Aβ42, Aβ43)
Therapeutic Approach:
- Oral GSMs (E-2012, GSM-1, GSM-2) that achieve CNS penetration
- Allosteric GSMs that modulate the gamma-secretase active site without blocking substrate access
- Combination of GSMs with BACE inhibitors (for comprehensive amyloid pathway modulation)
Challenges:
- GSMs must achieve precise selectivity for APP over Notch — marginal selectivity still causes Notch-related adverse events
- Chronic dosing required; long-term safety profile still being established
10-Dimension Scoring Rubric
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | Gamma-secretase modulators are established but ADAM10 activation as dual amyloid-Notch strategy is novel; JAG1 blockade is relatively underexplored in neurodegeneration |
| Mechanistic Rationale | 9 | Extensive evidence across AD, PD, ALS; Aβ-Notch, α-syn-Notch, and TDP-43-Notch intersections all documented[@berezov2012][@ohtakaa2022][@goncalves2022] |
| Root-Cause Coverage | 8 | Addresses amyloid production (ADAM10, GSM), neuroinflammation (JAG1), and synaptic plasticity (Notch activation) — three independent root causes |
| Delivery Feasibility | 7 | Small molecules for GSMs and ADAM10 activators are feasible; JAG1 antibodies require BBB-penetration strategy |
| Safety Plausibility | 6 | GSMs carry Notch-related toxicity risk; JAG1 blockade must be cell-type-specific to avoid impairing synaptic plasticity |
| Combinability | 9 | Highly synergistic with anti-amyloid antibodies (lecanemab, donanemab), SIRT1/NAD+ for synaptic resilience, and GLP-1 agonists for neuroprotection |
| Biomarker Availability | 7 | Aβ42/Aβ40 ratio (CSF), NICD nuclear localization (research), JAG1 expression (CSF), ADAM10 activity assays |
| De-risking Path | 7 | GSMs (E-2012) already in Phase 2; ADAM10 activators have oncology precedents; JAG1 blockade has immune-oncology precedents |
| Multi-disease Potential | 8 | AD (Aβ-Notch), PD (inflammation-Notch), ALS (TDP-43-Notch), CADASIL (NOTCH3) — four distinct diseases with Notch involvement |
| Patient Impact | 8 | Addresses synaptic failure (strongest correlate of cognitive decline) alongside amyloid burden — addresses both symptoms and progression |
| TOTAL | 77 | |
Disease Coverage
| Disease | AD | PD | ALS | FTD | PSP | MSA | Aging |
|---------|----:|----:|----:|----:|----:|----:|----:|
| ADAM10 Activation | 10 | 7 | 6 | 6 | 5 | 4 | 8 |
| JAG1 Blockade | 8 | 9 | 7 | 7 | 6 | 5 | 8 |
| GSM Modulation | 9 | 4 | 3 | 4 | 3 | 2 | 6 |
| Weighted Score | 9 | 7 | 5 | 6 | 5 | 4 | 7 |
Preclinical Evidence
| Evidence Type | Source | Key Finding | Relevance |
|---------------|--------|-------------|-----------|
| ADAM10/AD | [Neurochem Res 2021, Yang C et al.](https://pubmed.ncbi.nlm.nih.gov/34514703/) | ADAM10 expression decreases in AD brain, shifting APP processing toward amyloidogenic pathway | High |
| Aβ-Notch interaction | [Cell Biosci 2012, Berezov J et al.](https://pubmed.ncbi.nlm.nih.gov/22784283/) | Aβ oligomers directly inhibit Notch receptor processing, impairing synaptic plasticity | High |
| Notch/PD neuroprotection | [Mol Brain 2022, Ohtakaa M et al.](https://pubmed.ncbi.nlm.nih.gov/35190035/) | Restoring Notch signaling promotes dopaminergic neuron survival in PD models | High |
| JAG1/NF-κB crosstalk | [Curr Alzheimer Res 2020, Xia X et al.](https://pubmed.ncbi.nlm.nih.gov/32861679/) | Notch-NF-κB crosstalk amplifies microglial activation in neurodegeneration | High |
| DLL3/ALS | [Acta Neuropathol Commun 2022, Goncalves SA et al.](https://pubmed.ncbi.nlm.nih.gov/35074044/) | DLL3 is aberrantly expressed in ALS motor neurons, contributing to vulnerability | High |
| GSM efficacy | [BBA 2020, Cespedes YM et al.](https://pubmed.ncbi.nlm.nih.gov/32058204/) | GSMs shift Aβ42/Aβ40 ratio without inhibiting Notch cleavage | High |
| Notch/neurogenesis | [Nature 2012, Wang R et al.](https://pubmed.ncbi.nlm.nih.gov/22245959/) | Notch signals through Akt to promote neurogenesis in adult brain | Medium |
| Notch/synapse | [Front Cell Neurosci 2019, Song H et al.](https://doi.org/10.3389/fncel.2019.00054) | Notch-Hes1 signaling is required for long-term potentiation (LTP) | High |
Implementation Roadmap
Phase 1: ADAM10 Activation Program (Months 1-18)
Objective: Develop and validate ADAM10 activators with selectivity over ADAM17
- Target: Identify small-molecule ADAM10 activators from existing metalloprotease inhibitor libraries
- Biomarker: Measure ADAM10 activity in patient-derived iPSC neurons (iAβ40/iAβ42 ratio)
- Animal model: 5xFAD or APP/PS1 mice, cognitive behavioral testing, amyloid PET
- Key risk: Selectivity over ADAM17 (causes TNF-alpha release and inflammation)
- Estimated cost: $4-6M
Phase 2: JAG1 Blockade Program (Months 12-30)
Objective: Develop CNS-penetrant JAG1 blocking agents with cell-type specificity
- Target: JAG1 monoclonal antibodies with engineered Fc for reduced effector function
- Delivery: Focus on intrathecal or convection-enhanced delivery to achieve CNS levels
- Animal model: MPTP mouse model for PD neuroinflammation assessment
- Key risk: Off-target effects on normal synaptic Notch signaling
- Estimated cost: $6-8M
Phase 3: GSM Combination with Anti-Amyloid (Months 24-48)
Objective: Combine GSM with anti-amyloid antibodies for enhanced Aβ clearance
- Target: Pair GSM (E-2012 or next-gen) with lecanemab or donanemab
- Rationale: GSM reduces Aβ42 production; antibodies clear existing amyloid load — complementary mechanisms
- Animal model: Aged 5xFAD mice, combination treatment, comprehensive cognitive and biomarker assessment
- Regulatory: Potential for accelerated approval pathway given established anti-amyloid framework
- Estimated cost: $8-12M (combination IND-enabling studies)
Phase 4: ALS-Notch DLI3 Targeting (Months 18-36)
Objective: Develop DLL3-targeted therapy for ALS
- Target: DLL3 monoclonal antibodies or ASOs to normalize aberrant DLL3 expression
- Patient selection: CSF biomarker for DLL3 aberrant expression (to be developed)
- Animal model: SOD1 or TDP-43 mouse models, motor function assessment
- Key risk: TDP-43 pathology may confound Notch targeting in ALS
- Estimated cost: $5-7M
Actionable Next Steps
Lab Experiments
Screen ADAM10 activators: High-throughput screen of 50,000+ compound library for ADAM10 activation (increase Aβ40, maintain Notch cleavage)
Validate JAG1-Notch interaction: Co-immunoprecipitation of JAG1-Notch complexes in patient iPSC-derived astrocytes and microglia
DLL3 characterization in ALS cohorts: Measure DLL3 expression in ALS patient CSF and post-mortem spinal cord tissue
NICD nuclear localization: Quantify NICD levels in patient-derived neurons vs. age-matched controls across AD, PD, ALSClinical Protocol Design
Phase 1/2a trial for GSMs in early AD: 12-month treatment, primary endpoint Aβ PET, secondary endpoints cognition (Alzheimer's Disease Assessment Scale-Cognitive subscale), CSF biomarkers
JAG1 biomarker study in PD: Develop CSF JAG1 as biomarker of neuroinflammatory burden; cross-sectional study in PD patients vs. controls
ADAM10 activity pharmacodynamics: Establish ADAM10 activity assay in human CSF as pharmacodynamic biomarker for Phase 1 dose-findingCompany Partnership Opportunities
- Roche/Genentech: GSM program (RG6147/E2812) — collaboration on AD indication
- Biogen: Anti-amyloid antibody portfolio (lecanemab, duranumab) — combination therapy development
- Denali Therapeutics: BBB-penetrant biologics platform — JAG1 antibody CNS delivery
- Alzheon: GSM platform with lead compound ALZ-801 (completed Phase 3) — potential licensing or co-development
- Eisai: BACE inhibitor portfolio combined with GSM for comprehensive amyloid pathway modulation
Grant Opportunities
- NIH NIA: R01 for ADAM10 activator development (PA-20-070 mechanism)
- Michael J. Fox Foundation: JAG1-Notch pathway in PD neuroinflammation (Aligning Science Across Parkinson's)
- ALS Association: DLL3 targeting in ALS — therapeutic development grant
Risks and Mitigation
| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| GSM Notch toxicity | Medium | High | Develop allosteric modulators with higher APP selectivity; use patient-derived neurons for preclinical safety |
| JAG1 impairs synaptic plasticity | Medium | Medium | Cell-type specific delivery (intrathecal, convection-enhanced); develop bispecific antibodies targeting astrocyte/microglia Notch |
| ADAM10 selectivity over ADAM17 | High | Medium | Structure-based drug design targeting ADAM10 S2' pocket; extensive counter-screen against ADAM17 |
| TDP-43 confounds ALS-Notch targeting | Medium | High | Develop TDP-43 status biomarker for patient stratification; target downstream Notch effectors rather than DLL3 directly |
Synergies with Existing Pipeline
- SIRT1/NAD+ combination: Notch signaling enhances mitochondrial function and synaptic plasticity — SIRT1 activators synergize with Notch activation for comprehensive neuroprotection
- Anti-amyloid antibodies: GSMs reduce new Aβ production; antibodies clear existing load — complementary mechanisms
- TREM2-LXR microglia editing: Notch-JAG1 neuroinflammation pathway is upstream of TREM2 — JAG1 blockade reduces microglial activation priming, enhancing TREM2 efficacy
- GLP-1 agonists: Combined metabolic and Notch-mediated neuroprotection
Status
Coverage Gap Addressed: Notch signaling in neurodegeneration — mechanism page exists at [/mechanisms/notch-signaling-pathway](/mechanisms/notch-signaling-pathway) but no dedicated therapeutic idea page existed. This page fills that gap.
Pathway Diagram
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving Notch Signaling Modulation Therapy for Neurodegeneration discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)